Chordia Therapeutics (190A) · InitiativeRestated
Enrollment completed in the Japanese Phase 1 clinical trial of CTX-712
First written in FY2024-Q3. 1 of 2 entries say "Restated". Latest entry: FY2024.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Completion of patient enrollment in the Japanese Phase 1 clinical trial of CTX-712A theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「All patient enrollment had been completed by the end of August 2023, and 46 patients with solid tumors and 14 with hematologic cancers, for a total of 60 patients, had received treatment.」
The completion of enrollment in the Japanese Phase 1 trial and treatment of 46 patients with solid tumors, 14 with hematologic cancers and 60 patients in total have been reaffirmed. - FY2024-Q3First statedAnnual report
「For the CLK inhibitor CTX-712, we completed enrollment in the Japanese Phase 1 clinical trial, comprising 46 patients with solid tumors and 14 with hematologic cancers, for a total of 60 patients, by continuing enrollment with the cooperation of participating medical institutions despite the ongoing response to the COVID-19 pandemic.」
The completion of enrollment in the Japanese Phase 1 trial, comprising 46 patients with solid tumors, 14 with hematologic cancers and 60 patients in total, is reported.